Systemic @entity479 therapy is the only standard drug therapy for severe @entity1274 ( @entity1274 ). We have treated severe @entity1274 @entity1 with double combined therapy, intravenous @entity230 (IVS) and hyperbaric @entity26 (HBO). In this study, we retrospectively examined the effects of intratympanic @entity230 (ITS) by adding it to the double combined therapy. The study subjects were 172 @entity1 with severe @entity1274 . Eighty @entity1 (38 @entity1 and 42 @entity1 ) were treated with the double combined IVS and HBO therapy between April, 2007 and July, 2010 (A group: Historical control arm). Ninety-two @entity1 (51 @entity1 and 41 @entity1 ) were treated with triple therapy, combined therapy with IVS and HBO plus ITS, between August, 2010 and October, 2013 (B group: Current protocol arm). Each group was divided into two subgroups; one with a pure-tone average (PTA) between 60 and 89 dB ( @entity68096 and the other with a PTA >=  90 dB. @entity1938 , A2, B1, and B2 sub-groups had 56 (29 @entity1 , 27 @entity1 ), 24 (9 @entity1 , 15 @entity1 ), 64 (36 @entity1 , 28 @entity1 ), and 28 (15 @entity1 , 13 @entity1 ) @entity1 , respectively. All @entity1 were treated within 30 days from the onset. There was a statistically significant difference in hearing improvement between the @entity3750 groups, whereas no significant difference was observed between the @entity1938 groups. Furthermore, a significant difference was observed in all frequencies but 2 kHz between at the A2 group and B2 group, but not between the @entity1938 groups. Multivariate logistic analysis revealed that the treatment method (double vs.. triple combined therapies) had the strongest impact on hearing improvement in the @entity1274 @entity1 with a PTA >=  90 dB. These results indicated that the B2 group demonstrated better hearing improvement than the A2 group and suggested that the addition of the ITS could be effective for profound @entity1274 @entity1 with a PTA >=  90 dB.

[Intratympanic @entity479 Treatment for Severe XXXX ].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity1274 :: ('MESH:D006319', 'Disease') :: ['idiopathic sudden sensorineural hearing loss', 'ISSHL'] @entity68096 :: ('597;931', 'Gene') :: ['A1 and B1)'] @entity3750 :: ('23545', 'Gene') :: ['A2 and B2'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1938 :: ('597', 'Gene') :: ['A1 and B1', 'A 1'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity1274 :: (MESH:D006319,Disease) :: ['Idiopathic Sudden Sensorineural Hearing Loss']
